|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:esketamine_hydrochloride
|
|
gptkbp:approvalYear
|
2019
|
|
gptkbp:approvedBy
|
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:ATCCode
|
gptkb:N06AX27
|
|
gptkbp:brand
|
gptkb:esketamine
|
|
gptkbp:chemicalClass
|
gptkb:arylcyclohexylamine
|
|
gptkbp:contraindication
|
aneurysmal vascular disease
history of intracerebral hemorrhage
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Schedule_III_(US)
|
|
gptkbp:form
|
nasal spray
|
|
gptkbp:halfLife
|
7 to 12 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Spravato
|
|
gptkbp:legalStatus
|
prescription only (Rx-only)
|
|
gptkbp:manufacturer
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:pregnancyCategory
|
Not recommended
|
|
gptkbp:relatedTo
|
gptkb:ketamine
|
|
gptkbp:REMSProgram
|
gptkb:Spravato_REMS
|
|
gptkbp:riskFactor
|
dissociation
sedation
abuse and misuse
suicidal thoughts and behaviors
|
|
gptkbp:routeOfAdministration
|
nasal spray
|
|
gptkbp:sideEffect
|
nausea
dizziness
dissociation
sedation
increased blood pressure
|
|
gptkbp:usedFor
|
treatment-resistant depression
major depressive disorder with acute suicidal ideation or behavior
|
|
gptkbp:bfsParent
|
gptkb:Janssen
gptkb:Janssen_Sciences
gptkb:esketamine
gptkb:Esketamine
|
|
gptkbp:bfsLayer
|
7
|